FilingReader Intelligence
Ocumension glaucoma drug succeeds in phase III trial
August 21, 2025 at 12:10 PM UTC•By FilingReader AI
Ocumension Therapeutics announced its glaucoma drug OT-301 met its primary endpoint in a Phase III trial, showing non-inferiority to latanoprost for eye pressure reduction.
The company reported first-half revenue of RMB294.0 million, up 75.4% year-on-year, driven by ophthalmic product sales. Net loss was RMB132.3 million.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
HKEX:1477•Hong Kong Exchange
News Alerts
Get instant email alerts when Ocumension Therapeutics publishes news
Free account required • Unsubscribe anytime